نتائج البحث

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

• Authors : Layegh, Zohra¹ l.com; Ruwaard, Jill¹; Hebing, Renske C. F.^1,2

• Source: International Journal of Rheumatic Diseases. May2019, Vol. 22 Issue 5, p869-873. 5p.

تفاصيل العنوان

Efficacy and survival of infliximab in psoriasis patients: A single‐center experience in China.

• Authors : Chen, Wenjuan^1,2 (AUTHOR); Ding, Yangfeng^1,2 (AUTHOR); Lu, Jiajing^1,2 (AUTHOR)

• Source: Dermatologic Therapy. Nov/Dec2020, Vol. 33 Issue 6, p1-5. 5p.

تفاصيل العنوان

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series.

• Authors : Baraliakos, Xenofon¹ (AUTHOR); Tsiami, Styliani¹ (AUTHOR); Vijayan, Sooraj^2,3 (AUTHOR)

• Source: Clinical Case Reports. Jan2022, Vol. 10 Issue 1, p1-12. 12p.

تفاصيل العنوان

Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis.

• Authors : Matsuura-Otsuki, Yuki¹ ; Hanafusa, Takaaki²; Yokozeki, Hiroo²

• Source: Case Reports in Dermatology. May-Aug2017, Vol. 9 Issue 2, p26-29. 4p.

تفاصيل العنوان

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series

• Authors : Xenofon Baraliakos; Styliani Tsiami; Sooraj Vijayan

Subjects: COVID‐19; CT‐P13 SC; infliximab SC

• Source: Clinical Case Reports, Vol 10, Iss 1, Pp n/a-n/a (2022)

تفاصيل العنوان

Changes in Body Mass Index and Lipid Profile in Psoriatic Patients After Treatment With Standard Protocol of Infliximab.

• Authors : Ehsani, Amir Houshang¹; Mortazavi, Hossein¹; Balighi, Kamran¹

• Source: Acta Medica Iranica. 2016, Vol. 54 Issue 9, p570-575. 6p.

تفاصيل العنوان

Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study

• Authors : Fautrel, Bruno; Bouhnik, Yoram; Dieude, Philippe ...

Subjects: Trial registration: clinicaltrials.gov NCT03662919 SB2 biosimilar infliximab switch rheumatoid arthritis psoriatic arthritis axial spondyloarthritis; Trial registration: clinicaltrials.gov; NCT03662919 SB2

• Source: EISSN: 2514-1775 ; Rheumatology Advances in Practice ; https://hal.sorbonne-universite.fr/hal-04087107 ; Rheumatology Advances in Practice, 2023, 7, ⟨10.1093/rap/rkad031⟩

تفاصيل العنوان

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.

• Authors : Waller, John¹; Sullivan, Emma¹; Piercy, James¹

• Source: Patient Preference & Adherence. Mar2017, p519-530. 12p.

تفاصيل العنوان

Development of Eosinophilic Fasciitis during Infliximab Therapy for Psoriatic Arthritis.

• Authors : Hariman, Richard¹; Patel, Payal¹; Strouse, Jennifer¹

• Source: Case Reports in Rheumatology. 5/11/2016, p1-4. 4p.

تفاصيل العنوان

Infliximab: Efficacy in psoriasis.

• Authors : Arsiwala, Shehnaz¹

• Source: Indian Journal of Dermatology, Venereology & Leprology. Jul2013 Supplement 1, Vol. 79, pS25-S34. 10p.

تفاصيل العنوان